H. R. 3810

To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

June 5, 2023

Ms. Eshoo introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Drug Origin Transparency Act of 2023”.

SEC. 2. ENHANCED DRUG MANUFACTURING AMOUNT INFORMATION REPORTING.

(a) In General.—Section 510(j)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360(j)(3)) is amended—
(1) in subparagraph (A), by adding “or (2)” after “paragraph (1)”; and

(2) by adding at the end the following:

“(C) Each report submitted pursuant to sub-
paragraph (A) with respect to a drug shall—

“(i) include additional information as may be specified by the Secretary in regulation or guidance regarding the supply chain for such drug, such as—

“(I) the identity of the respective sup-
pliers of each active pharmaceutical ingre-
dient, active pharmaceutical ingredient in-
termediate, and in-process material used in such manufacture, preparation, propaga-
tion, compounding, or processing of the drug; and

“(II) the respective amounts of such drug that were manufactured, prepared, propagated, compounded, or processed using an active pharmaceutical ingredient, active pharmaceutical ingredient inter-
mediate, and in-process material from each such identified supplier; and

“(ii) be submitted more frequently than annually, in accordance with a reporting sched-
ule as may be specified by the Secretary in such
regulation or guidance, but not more frequently
than 4 times per year.

“(D) Any additional information specified in
regulation or guidance pursuant to subparagraph
(C) shall be a required element of reports under this
paragraph not earlier than 6 months after the date
on which such regulation or guidance is issued in
final form (and in no event shall the absence of any
regulation or guidance issued under subparagraph
(C) affect the requirement to report as described in
subcategory (A)).”.

(b) Conforming Amendment.—Section
510(j)(3)(B) of the Federal Food, Drug, and Cosmetic
Act (21 U.S.C. 510(j)(3)(B)) is amended by striking “sub-
paragraph (A)” and inserting “this paragraph”.

SEC. 3. REQUIRE DRUG LABELING TO INCLUDE ORIGINAL
MANUFACTURER AND SUPPLY CHAIN INFOR-
MATION.

Section 502 of the Federal Food, Drug, and Cosmetic
Act (21 U.S.C. 352) is amended—

(1) in paragraph (b)—

(A) by striking “(b) If in a package” and
inserting “(b)(1) If in a package”;
(B) by striking “a label containing (1) the name and place” and inserting “a label containing—
“(A) the name and place”;
(C) by striking “or distributor; and (2) an accurate statement” and inserting “or distributor; and
“(B) an accurate statement”;
(D) by striking “under clause (2) of this paragraph” and inserting “under this clause”; and
(E) by inserting at the end the following:
“(2)(A) Subject to clause (C), if it is a drug, including an active pharmaceutical ingredient, unless it bears a label containing the name and place of business, and unique facility identifier of the original manufacturer of such drug or active pharmaceutical ingredient, except that the Secretary may provide, by regulation, for reasonable variations in the implementation of such labeling requirements.
“(B) Subject to clause (C), if it is a drug that is an active pharmaceutical ingredient, unless any accompanying certificate of analysis contains the name and place of business, and unique facility iden-
tifier of the original manufacturer of the active pharmaceutical ingredient.

“(C) The Secretary may provide, by regulation, for reasonable variations in the implementation of labeling requirements specified in this subparagraph.”; and

(2) by inserting after paragraph (e) the following:

“(d)(1) Subject to subparagraph (2), if it is a drug, including an active pharmaceutical ingredient, unless it bears labeling containing the name and place of business of—

“(A) the original manufacturer of each active pharmaceutical ingredient;

“(B) each manufacturer, if different from the original manufacturer; and

“(C) the packer or distributor, if any.

“(2) The Secretary may provide, by regulation, for reasonable variations or an alternative placement for the labeling requirements specified in subparagraph (1), including by electronic means.”.